The invention relates to a transdermal therapeutic system for the controlled release of water-soluble pharmaceutical active ingredients from an aqueous phase, comprising an occlusive back layer, a central device facing the skin for releasing the agent, an adhesive layer concentrically surrounding the dispensing device and a removable protective film. Said device is made from a stationary solid phase and a liquid phase containing the active ingredient in aqueous solution, the solid phase being formed from a solid with a fleecy or spongy structure.

This invention relates to a pharmaceutical preparation for the treatment of compromised tissue such as skin wounds and ulcers in humans and animals and a method of preparation. This is a multifunctional natural matrix meant for the treatment of compromised tissues which also relates to the anti-cancer transdermal patch for melanoma therapy. Further, the invention comprises for the treatment of Alzheimer's, and multiple sclerosis also. The composition consists of water-solubilized nano-sized formulation of non-aqueous solvent extract of phyto-pharmaceuticals in herbal, animal or synthetic biocompatible gel or on matrix coated or both. The composition is used as a topical device for the treatment of compromised tissues in its preferred embodiment.

Embodiments of stable topical compositions for administering fenoldopam (compound (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed for immediate or continued slow release administration, over prolonged periods of time with safe minimal systemic exposure of fenoldopam (reducing the risk for lowering blood pressure). The compositions include those compositions that increase the stability and skin absorption of the drug, particularly anhydrous semi-solid compositions and creams. This is accomplished by incorporating fenoldopam in soluble or dispersed form into semi-solid compositions like ointments or anhydrous gels that are not irritative. Embodiments of methods for using the topical compositions in the treatment of dermatological disorders including psoriasis, alopecia atopic dermatitis and vitiligo are disclosed. ##STR00001##

The present invention provides a composition for preventing, ameliorating, alleviating or treating dermatitis comprising exosomes derived from adipose-derived stem cells as an active ingredient. The composition of the present invention is able to act against dermatitis-inducing multiple cytokine targets, and thus be widely applied against dermatitis caused by various factors and effectively suppress and alleviate dermatitis.

The present disclosure provides a transdermal delivery systems for delivering donepezil free base to patients suffering from central nervous system disorders including dementia and Alzheimer's. The transdermal delivery systems can have a separating layer having at least one surface with a surface energy of at least 40 Dynes, sodium bicarbonate particles in the drug matrix layer where the sodium bicarbonate particles have a D90 particle size of from 0.1 μm to 1000 μm, or a combination thereof.

Natural honey and a surfactant are combined to achieve a novel wound treatment composition. The honey is chosen for its medicinal properties, and the surfactant is used for biofilm removal to enhance the effectiveness of the honey. In preferred embodiments, the honey is a tropical honey currently sourced from Mexico. The surfactant is mixed with water, then the aqueous mixture is combined with the honey. In accordance with a preferred embodiment, a surfactant powder is mixed with water at a ratio of 10% powder to water, then that mixture is combined with honey at a ratio greater than 50:50, more preferably at a ratio of 90:10. The currently preferred surfactant is Poloxamer 188. The product may be applied directly to a wound or applied to wound dressings including, without limitation, gauze, gauze rolls, hydrocolloids, and calcium alginate dressings.

The disclosure relates to compounds and compositions for sustained release of ocular therapeutics.

The present invention relates to a method for producing a drug delivery system. The method comprises the steps of screen-printing a base paste, and curing the base paste. Furthermore, the method comprises the steps of screen-printing a first paste separate to the base paste, and curing the first paste.

A method for reducing skin sensitization of an asenapine-containing patch comprising a backing layer and an adhesive agent layer, the method comprising: using an adhesive agent for preparing the adhesive agent layer, the adhesive agent containing free asenapine in a range of 2 to 5% by mass, styrene-isoprene-styrene block copolymer (SIS) in a range of 7 to 18% by mass, polyisobutylene (PIB) in a range of 0.5 to 10% by mass, alicyclic saturated hydrocarbon resin in a range of 30 to 70% by mass, and liquid paraffin in a range of 5 to 10% by mass, relative to a total amount of the adhesive agent; and preparing the asenapine-containing patch whose average cumulative amount of skin permeation of asenapine (24 hours) after applying the asenapine-containing patch to skin of a dorsal scapular region of a 5-week-old Hartley white female guinea pig and holding the asenapine-containing patch with an occlusive dressing for 24 hours is in a range of 90 to 300 μg/cm.sup.2 in terms of free form.

The present disclosure relates to a tongue spray containing gymnemic acid together with a form of exogenous ketones. The present disclosure also relates to methods of reducing or eliminating sugar consumption and reducing sugar withdrawal symptoms via administration of such composition to a subject.